A Phase 3 interventional study of Masitinib and Placebo in Multiple Myeloma, sponsored by AB Science. Terminated at 13 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-12-19.
Sponsored by AB Science · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 377 studies in Multiple Myeloma with a site in France — 73 open to participants now, 137 under way, 49 of them phase 3. Multiple Myeloma · France.
Among the 377 studies in Multiple Myeloma with a site in France, this one is the 155th largest by enrollment of the 316 interventional ones that give a count, is one of 11 that started in 2011, is one of 106 in phase 3, and was the 72nd registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →73 of the 377 studies in Multiple Myeloma with a site in France are open now. Recruiting first, the newest first:
AstraZeneca · Sites in France, United States, Australia and 15 more countries
Ages 18–130
CSL Behring · Sites in France, United States, Belgium and 8 more countries
Ages 18+
Janssen Research & Development, LLC · Sites in France, Australia, Czechia and 11 more countries
Ages 18+
Janssen Research & Development, LLC · Sites in France, United States, Argentina and 7 more countries
Ages 18+
AstraZeneca · Sites in France, United States, Australia and 12 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
377 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 94 · Phase 2 116 · Phase 3 108 · Phase 4 2
First in 1997; this study’s year is marked. 11 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 147 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 138 across the 316 interventional studies, 203 across the 60 observational. Of the 221 that completed or were terminated, 85 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
232 of 377 have an industry lead sponsor. The 10 most frequent:
AB Science is the lead sponsor of 39 studies on the registry; 5 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
AB Science has 2 studies filed under Multiple Myeloma — fewer than ten, so there is no comparison to draw.
29 of the studies in Multiple Myeloma with a site in France that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05519085Phase 3CelgeneA Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | 2027-01-10 |
| NCT03319667Phase 3SanofiA Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | 2027-04-05 |
| NCT05455320Phase 3Janssen Research & Development, LLCA Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment | 2027-07-30 |
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT05317416Phase 3PfizerStudy With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant | 2027-08-04 |
Add all 29 to your calendar (.ics) → With an account.
Among the 377 studies in Multiple Myeloma with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to compare the efficacy and safety of masitinib 6 mg/kg/day in combination with bortezomib and dexamethasone to placebo in combination with bortezomib and dexamethasone in the treatment of patients with relapsing multiple myeloma who have received one previous therapy.
This is a prospective, multicenter, randomized, double-blind, placebo-controlled, 2-parallel group, phase 3 study to compare efficacy and safety of masitinib 9 mg/kg/day to placebo in the treatment of patients with relapsing multiple myeloma who received one previous therapy.
Patients will receive study treatment (masitinib/placebo) with the standard therapy (bortezomib and dexamethazone).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Masitinib (6 mg/kg/day) in combination with Bortezomib and Dexamethasone
Drug: Masitinib · Drug: Bortezomib · Drug: Dexamethasone
Placebo in combination with Bortezomib and Dexamethasone
Drug: Placebo · Drug: Bortezomib · Drug: Dexamethasone
Masitinib 6 mg/kg/day
Also known as: AB1010
Matching placebo
Standard therapy (cycles of bortezomib)
Also known as: Velcade
Standard therapy (cycles of dexamethasone)
Also known as: Dexasone
Progression Free Survival
Time frame: Analysis to be conducted after a minimum of 201 events
Overall Time to Progression
Time frame: time from the date of randomization to the date of documented progression during the study
Overall Survival
Time frame: Until death
Ran from May 2011 to primary completion in Jan 2017, 68 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Masitinib